TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07589595: A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Co

Sponsor: Eli Lilly and Company · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 350 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$6,308,000

Rescue Site Savings

+$4,150,000

Unlock Full NCT07589595 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07589595 Rescue Dossier →